(Q38568711)

4 September 2017

Switching P2Y12-receptor inhibitors in patients with coronary artery disease (English)

1 reference

4 September 2017

1 reference

ChEBI release 2020-05-28

3

Dominick J Angiolillo

1 reference

4 September 2017

Fabiana Rollini

1

1 reference

4 September 2017

Francesco Franchi

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

18 August 2015

1 reference

Nature Reviews Cardiology

4 September 2017

1 reference

4 September 2017

13

1 reference

4 September 2017

1

1 reference

4 September 2017

11-27

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2015.113

4 September 2017

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pretreatment with P2Y12 inhibitors in non-ST-Segment-elevation acute coronary syndrome: an outdated and harmful strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Basic principles of platelet biology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Novel antiplatelet agents in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Biology and pharmacology of the platelet P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Cangrelor: a review on pharmacology and clinical trial development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

A comparative pharmacodynamic study of ticagrelor versus clopidogrel and ticagrelor in patients undergoing primary percutaneous coronary intervention: the CAPITAL RELOAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Platelet function testing in contemporary clinical and interventional practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching acute coronary syndrome patients from prasugrel to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Long-term use of ticagrelor in patients with prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Effect of platelet inhibition with cangrelor during PCI on ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic effects during the transition between cangrelor and ticagrelor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reac

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Bedside monitoring to adjust antiplatelet therapy for coronary stenting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Switching from prasugrel to clopidogrel: navigating in unknown waters

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

Pharmacodynamic effects during the transition between cangrelor and prasugrel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2015.113

ADP receptors of platelets and their inhibition

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26283269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26283269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Switching from clopidogrel to prasugrel in patients having coronary stent implantation.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26283269

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2015.113

1 reference

Dimensions Publication ID

4 September 2017

0 references

1 reference